Treatment with Stalevo and Comtan Does Not Raise Prostate Cancer Risk, FDA Finds

A review by the U.S. Food and Drug Administration (FDA) found that Parkinson’s patients treated with medications containing entacapone are at no increased risk of prostate cancer. As such, the agency stands by its current recommendations for the use of Stalevo (entacapone/carbidopa/levodopa) and Comtan (entacapone; brand name is Comtess…